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Abstract 
This review has three objectives, namely: (i) to discuss how oral cancer is and ought to be 
defined and recorded; (ii) to present up to date data on the incidence burden of the disease 
in the four countries of the UK, and review recent analyses of trends in the disease; and (iii) 
to summarise recent evidence on risk factors of the disease. Emerging evidence of the role 
played by risk factors in different anatomical sites means that oral cavity cancer and 
oropharynx cancer should be considered distinct disease entities – and a standardised 
attribution of anatomical subsites will be helpful in ensuring consistency in how data are 
presented. In 2016, over 3,700 people were diagnosed with oral cavity cancer and over 
3,500 people were diagnosed with oropharyngeal cancer in the UK. Incidence of 
oropharyngeal cancer is rapidly rising across the UK. Rates of oral cavity cancer are higher 
in N.Ireland and higher still (and relatively stable) in Scotland, but rising in England and 
Wales. The International Head and Neck Cancer Epidemiology (INHANCE) consortium have 
pooled data from multiple case-control studies providing the best estimates of risk factors. 
They show that while the consumption of alcohol and tobacco are the prime risk factors for 
oral cavity and oropharyngeal cancers, they provide greater certainty in the preventive 
benefits of reducing these risk factors. The role played by other factors such as low 
socioeconomic status, genetics, oral health, and Human Papillomavirus (only for 
oropharyngeal cancer) have become clearer.  
 
Key points:   
 This paper discusses issues affecting the definition of oral cancer and makes the 
case that emerging differences in the aetiology of the disease at different sites 
requires oral cavity cancer and oropharyngeal cancer to be clearly defined, recorded, 
and reported separately. 
 In 2016, over 3700 people were diagnosed with oral cavity cancer and over 3500 
people were diagnosed with oropharyngeal cancer in the UK. Incidence of 
oropharyngeal cancer is rapidly rising across the UK. Rates of oral cavity cancer are 
higher in N.Ireland and higher still (and relatively stable) in Scotland, but rising in 
England and Wales. 
 Pooled international case-controlled study data are shedding increasing light not only 
on the causes of oral cavity and oropharyngeal cancers, but on the impact of 
avoiding risk factors.  
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Introduction 
Epidemiology 
The term “epidemiology” is derived from the Greek word “epidemion”, a verb meaning “to 
visit” used in connection with human illnesses in the writings of Hippocrates, who in addition 
referred to the term in the distribution of disease in the population as per it’s Greek language 
origins “epi” about and “demos” people [1]. According to Buck and colleagues (1988), the 
first published use of the word was the Spanish “epidemiologia” in a study of the bubonic 
plague and it became the term employed for the study of communicable disease epidemics 
[1]. Since then epidemiology has continually evolved as a scientific discipline, investigating a 
wide range of non-communicable as well as communicable diseases and health outcomes – 
including cancer. The focus is always on populations rather than individuals – although the 
findings of epidemiological studies can have implications and applications for individuals as 
well as populations.   
The main cancer epidemiology approaches involve:  
 describing the burden and natural history of disease in populations (descriptive 
epidemiology) – which is the mainstay of cancer surveillance. This provides insights 
and the development of hypotheses around potential causes which can be tested 
using analytical study designs 
 analysing the aetiological determinants or risk factors for cancer (analytical 
epidemiology) [2].  
Understanding the burden and causes of cancer is essential for developing and evaluating 
healthcare services and prevention programmes. 
 
Oral Cancer 
There is a lack of consensus on the definitions of oral cancer in the literature and multiple 
terms are used. This is further complicated with “head and neck cancer” terminology [3,4]. 
Quantitative analysis of disease relies on clear and uniform definitions and this is 
fundamental to cancer epidemiology, including definitions of topography (site), morphology 
(histopathology), and tumour behaviour (invasion – malignant, benign, in-situ).  
 
However, in relation to oral cancer, there are also variations in the anatomical subsites 
included in oral cavity and oropharynx groupings. Different sources attribute some sites to 
the oral cavity, whilst others define the same site as oropharynx.  Yet others include some 
sites under both. Precision in what is termed “oral cavity” and “oropharynx” is thought 
increasingly important due to epidemiological data showing the emerging role of human 
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papillomavirus (HPV) in cancer aetiology. Understanding of the role played by HPV 
(especially in oropharynx cancer) is leading to the identification of differing trends and risk 
profiles alongside differing treatment regimen and prognoses [5]. Thus, oral cancer is 
increasingly being recognised as being two distinct diseases: oral cavity cancer (OCC) – 
“mouth cancer” and oropharyngeal cancer (OPP) – “throat cancer”.  
This paper has three aims:  
 to achieve clarity on the definitions of oral cavity cancer and oropharyngeal cancer, 
 to present the recent global and UK trends in the incidence of these cancers, 
 to describe the current evidence on their risk factors.   
 
Methods 
Defining oral cavity cancer and oropharyngeal cancer  
The International Classification of Diseases for Oncology (ICD-O), published by the World 
Health Organization, is the standard classification tool for defining cancer subsites (along 
with morphologies). It is revised every ten years, most recently in 2013 [6]. This paper 
reviews the ICD-O codes used to define oral cavity cancer and oropharyngeal cancer within 
UK cancer registries and compares this with emerging definitions used in recent major 
epidemiology publications. Taking account of any variation in these definitions and 
considering both anatomical and aetiological differences in subsite grouping, this paper will 
try to present distinct standardised definitions of oral cavity cancer and oropharyngeal 
cancer.   
 
Descriptive epidemiology of the burden and trends in oral cavity cancer and 
oropharyngeal cancer  
The incidence (risk) burden of cancer in a population is best measured by incidence rates. 
Cancer incidence rates are the number of new cases diagnosed in the population over a 
given period of time (usually a year) expressed as a rate by dividing this by the total 
population at risk during that period (denominator). The denominator is usually adjusted to 
account for different age profiles in different populations referenced to a standard population, 
which has a known population age-structure – this is often the European Standard 
Population, which is a theoretical population adding up to a total of 100,000 persons.  
Incidence rate data are usually available from routinely collected data in Cancer Registries. 
Cancer Registration is the collection, maintenance, and management of data on every new 
diagnosis of cancer occurring in a population (obtained from multiple records including 
hospital medical and pathology records, death records). It uses the ICD-O to code the 
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topography (site) and morphology (histopathology) of the primary tumour along with basic 
demographic data.  
 
This paper summarises the findings from recent global and UK epidemiological trend 
analyses peer-reviewed publications. Findings from global and UK studies which have 
analysed separately the recent trends in the incidence rates of oral cavity and oropharyngeal 
cancers are also reviewed. In addition up-to-date information requests were submitted to the 
UK Cancer Registries for annual incidence rates standardised to the 2013 European 
Standard Population (and number of new cases) of oral cavity and oropharyngeal cancer 
from 2000 to the most recently available year. In the UK there are 12 cancer registries, 
including one each for Northern Ireland (N.Ireland) [7], Scotland [8], and Wales [9], the 
English regional cancer registries collate their data via the National Cancer Registration and 
Analysis Service (NCRAS) in Public Health England [10]. Where available, these data will be 
presented separately by gender for each country of the UK – this will follow a more strictly 
defined subsite criteria of oral cavity cancer and oropharyngeal cancer. Epidemiological 
trends in mortality and survival of oral cavity and oropharyngeal cancer are beyond the 
scope of this paper. 
 
Analytical epidemiology of risk factors for oral cavity cancer and oropharyngeal 
cancer 
Risk factors for cancer studies are usually ascertained from observational studies – cohort or 
case-control studies. Given the relatively low volume of oral cancer and the long lag-time 
between exposure to risk factors and cancer diagnosis, case-control study designs are the 
mainstay of epidemiological investigations. In such case-control studies, a group of patients 
with oral cancer (“cases”) and a comparable group of study participants without oral cancer 
(“controls”) are recruited. Information on their histories of exposure to risk factors is collected 
and compared and differences allow assumptions to be made on possible risk and 
aetiological factors   
 
The International Head And Neck Cancer Epidemiology (INHANCE) consortium is a 
collaboration of research groups of large epidemiological (case-control) studies investigating 
the risk factors for head and neck cancer including (separately) oral cavity and 
oropharyngeal cancer subsites [11, 12]. The consortium has pooled and standardised data 
from 35 studies including data on over 25,500 patients with head neck cancer (including 
cancers of the oral cavity and oropharynx) and 37,100 controls (participants without cancer). 
Over 30 peer-reviewed publications analysing aspects of the INHANCE data have been 
published. These have focused in detail on tobacco and alcohol risks, along with other key 
and emerging risk factors. This big dataset has major strengths including providing more 
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precise estimates of risk and has the ability to control for and assess interactions with 
potential confounding factors. The findings of the INHANCE data analyses with a particular 
focus on oral cavity and oropharyngeal cancers are presented below. Where there are gaps 
in the INHANCE analyses, these data have been complemented with other published 
systematic reviews or meta-analysis.  
 
 
Results and discussion 
Definitions 
The debate over definitions is encapsulated and exemplified by the variation in routine 
publication of oral cancer statistics in the UK Cancer Registries (Table 1). Both the Cancer 
Registration statistics for England [10], published by the Office for National Statistics, and 
the Northern Ireland Cancer Registry [7], define oral cancers as one grouping “lip, oral 
cavity, and pharynx” – with the pharynx including oropharynx as well as nasopharynx and 
hypopharynx sites. The Cancer Registry for Wales [9], now known as the Welsh Cancer 
Intelligence and Surveillance Unit combine “oral & oropharynx cancer” together in their 
Cancer Incidence in Wales online publication. The Scottish Cancer Registry [8] report 
multiple subgroupings of head and neck cancer including “oral cavity cancer” and 
“oropharynx cancer” – however, there are a number of ICD codes included in both oral cavity 
and oropharynx definitions (Table 1). 
 
Based on a review of major epidemiological studies [13-16], a “compromise” (anatomical and 
HPV-associated) method of defining oral cavity and oropharyngeal cancers separately was 
developed and is used here in a reanalysis of UK cancer data and proposed for future 
epidemiological studies (Table 1). Briefly, oropharyngeal cancer has been defined as 
including: the base of the tongue (C01), lingual tonsil (C2.4), tonsil (C09), oropharynx (C10), 
and pharynx not otherwise specified (C14); while oral cavity cancer includes: the inner lip 
(C00.3 - C00.9), other and unspecified parts of the tongue (C02) [excluding lingual tonsil 
(C2.4)], gum (C03), floor of the mouth (C04), palate (C05), and other and unspecified parts 
of the mouth (C06).  
 
[INSERT TABLE 1 HERE] 
 
Global burden and trends 
The best and most recently available peer-reviewed analyses of global estimates by the 
World Health Organisation International Agency for Research on Cancer (WHO IARC) are 
for 2012 when 202,000 cases of oral cavity cancer and 100,500 cases of oropharyngeal 
cancer were newly diagnosed that year [17]. The global estimated age-standardised rate of 
7 
 
oral cavity cancer was 2.7 per 100,000 in 2012, with the largest proportion (48.7%) 
diagnosed in south-central Asia, and occurrence being consistently higher in men than 
women (M:F rate ratio 2:1). The global estimated rate for oropharyngeal cancer was lower at 
1.4 per 100,000 in 2012, (but with a higher M:F ratio of 4.8:1), with the highest proportions 
being in North America (34.2%) and South-central Asia (35.1%) [17].  
 
A series of detailed epidemiological studies on the worldwide and US trends in incidence 
rates for oral cavity and oropharyngeal cancers have been undertaken in recent years 
[13,14,17,18]. These analyses show that the incidence of oropharyngeal cancer is rising 
rapidly, especially in high income countries and especially in the US.  In contrast oral cavity 
cancer incidence rates are flat-lining or decreasing in men globally and increasing slightly in 
women [14]. These changing trends are a global phenomenon and have been related to 
changing population risk factors. This has been described as “controlling a tobacco epidemic 
while a human papillomavirus epidemic emerges” [19]. 
 
UK burden and trends 
Recently, there have been two studies of trends in oral cavity and oropharyngeal cancer in 
the UK. In England, oral cavity cancer increased per annum by 2.8% for men and 3.0% for 
women, while oropharynx cancer increased by 7.3% for men and 6.5% for women between 
1995 and 2011 [15]. Further annual increases were projected from 2011 to 2025. In 
Scotland, a recent cancer registry analysis showed that between 2001 and 2012 
oropharyngeal cancer increased by 85%, while oral cavity cancer increased by only 10% 
[16]. Oropharyngeal cancer has also been shown to be the most rapidly rising cancer in 
Scotland [20]. These observed trends are more marked among men [15, 16, 20], and the 
burden of both oral cavity and oropharyngeal cancer is greater among those from more 
deprived communities [16]. Analysed projections of these England and Scotland rates 
showed that the incidence burden of oropharyngeal would overtake oral cavity cancer within 
the next decade [15, 16]. 
 
Table 2 shows the most up-to-date available numbers and incidence rates of oral cavity and 
oropharyngeal cancer by males and females for England, N.Ireland, Scotland, and Wales. 
 
[INSERT TABLE 2 HERE] 
[INSERT FIGURE 1 HERE] 
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For the most recently available data – 2016, there were 3088 people diagnosed with oral 
cavity cancer in England, 80 in N.Ireland, 400 in Scotland, and in Wales (in 2015) there were 
176 people diagnosed – giving a total of 3744 people diagnosed with oral cavity cancer in 
the UK. In 2016, there were 2977 cases of oropharyngeal cancer diagnosed in England, 73 
in N.Ireland, and 324 in Scotland, and in Wales (in 2015), there were 207 people diagnosed 
– giving a total of 3581 people diagnosed with oropharyngeal cancer in the UK, and a total of 
7325 cases of oral cavity and oropharynx cancers combined. This gives a total number of 
patients so far this century, recorded in the UK cancer registries as diagnosed with oral 
cancer of 90,880 (52,829 oral cavity and 38,051 oropharyngeal – Figure 1)). 
The trends in the incidence rates of oral cavity and oropharyngeal cancer for England, 
N.Ireland, and Scotland (2000-2016), and for Wales (2000-2015) are shown in Figure 1. A 
rapid increase in oropharyngeal cancer incidence is observed in all four countries. Oral 
cavity cancer incidence rates in Scotland have been relatively stable and consistently at the 
highest levels; in N.Ireland have a near similar magnitude, but are less stable (likely due to 
small numbers); while they have steadily risen in England and Wales over the period. 
Oropharyngeal cancer incidence rates are converging and catching up on oral cavity cancer 
rates in England, N.Ireland, and Scotland, but in Wales oropharyngeal cancer rates have 
already surpassed oral cavity cancer rates (Figure 1). 
 
Risk factors review 
Tobacco smoking and alcohol  
Tobacco smoking and alcohol intake are well established risk factors for oral cancer. The 
INHANCE pooled dataset and analyses provide sufficiently high numbers of oral cavity and 
oropharyngeal cases who were non-smokers and/or non-alcohol consumers (thereby 
avoiding the problems associated with confounding) to enable a better understanding of 
these risks. This includes providing precise estimates of risk, understanding the joint 
tobacco-alcohol interaction, investigating the risk of smokeless tobacco and the benefits of 
quitting smoking or alcohol drinking.  
 
Among smokers who never drank alcohol, there was a 2-fold risk estimate for oral cavity and 
oropharyngeal cancer, which increased with frequency and duration of smoking. A similar 2-
fold risk of oral cavity and oropharyngeal cancer for alcohol drinking among those who never 
smoked tobacco was found, but only in heavier alcohol drinkers (three or more drinks per 
day) [21]. The highest risks are observed in those who both smoked tobacco and consumed 
alcohol heavily, with risk increased 5-fold [22].   
INHANCE data show that there is a strong dose-response relationship for the risk of oral 
cavity and oropharyngeal cancer, with increasing frequency and duration of both smoking 
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and alcohol consumption. As is the case for lung cancer risk [23], smoking duration is more 
important than frequency for oral cancer – with fewer cigarettes per day over a longer 
number of years having a higher level of risk for oral cancer than more cigarettes per day 
over fewer years [24]. However, for alcohol consumption frequency is more important than 
duration – such that higher consumption (more than three drinks per day) over a short period 
(a few years) has a higher risk for oral cancer than a lower intake over a longer period (many 
years). Moreover, for both smoking and alcohol consumption there was no safety in low 
doses – low intakes of cigarettes and alcohol drinking increased risk of oral cancers [25]. In 
head and neck cancer risks – smoking risks were generally greater for larynx cancer, and 
alcohol drinking for oral cavity and pharyngeal cancers [24]. 
Betel quid  
Betel quid, also known as “paan”, is a mixture of substances including areca nut with or 
without tobacco wrapped in a betel leaf and placed in the mouth [26]. It is common in south 
and southeast Asia and among people of south Asian origin in communities across the world 
including the UK [27, 28]. In a systematic review and meta-analysis of 15 case-controls, 
betel quid without tobacco was shown to have a near 3-fold increased risk association with 
“oral cancer” (undefined) [26].  
 
Smokeless Tobacco 
INHANCE analyses of smokeless tobacco – consumed as powdered snuff or tobacco 
chewing, found an increased risk association for oral cavity cancer, with a near 2-fold risk 
even among never cigarette smokers [29]. It therefore cannot be considered a risk reduction 
alternative. 
 
The benefits of stopping smoking and drinking alcohol 
Demonstrable benefits of quitting smoking were identified from the INHANCE data.  Within 1 
to 4 years after stopping smoking, risks reduced and reached a similar level to those who 
had never smoked after 20 years of quitting. In contrast, the risk effects associated with 
quitting heavy alcohol consumption take 20 years to begin to emerge [30]. 
 
Socioeconomic status 
The other major risk association identified, on par with smoking and alcohol in terms of 
magnitude (2-fold increased risk), was socioeconomic status – specifically low educational 
attainment and low income. These risks were not fully explained by smoking and alcohol 
consumption – such that these socioeconomic effects were influencing risk behaviours (“the 
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cause of the cause”) and potentially having a more direct effect associated with 
socioeconomic circumstances [31]. 
 
Diet 
There was limited new evidence in relation to dietary factors beyond confirming that a high 
intake of fresh fruits and vegetables were associated with reducing by half the oral cancer 
risk [32]. It is notable that, unlike for many cancers [33], obesity was not associated with an 
increased oral cancer risk. In fact, there are data to suggest that in young people (aged 30-
years or less) oral cancer was more likely in those who self-reported a low body mass index 
(BMI) [34].    
 
Genetics 
Some limited risk associations associated with oral cancer have been identified – including 
genetic variants associated with alcohol metabolism, DNA repair pathways, and genes 
involved in the metabolism of nicotine [35]. This work has demonstrated the potential of 
genetic-environmental risk interactions. A moderately strong family history hereditary risk 
was also identified.  An increased risk associated with having a first degree relative with 
head and neck cancer has been suggested [36]. 
 
Young people 
Interestingly, risk factors reported above were generally consistent across age-groups (and 
indeed genders), with the major risk factors observed among younger adults being tobacco 
smoking and alcohol drinking [37].  
 
Oral health  
The risks associated with poor oral health are also beginning to become clear through 
analysis of the INHANCE dataset. After adjusting for smoking and alcohol consumption: few 
missing teeth, regular dental attendance, and daily toothbrushing may modestly reduce the 
risk of oral cavity and oropharyngeal cancer, but wearing a denture per se was not 
associated with increased risk [38, 39]. There was also a slightly elevated risk associated 
with mouthwash use over a prolonged period (greater than 35 years) and use more than 
once per day – although it was not possible to completely disentangle smoking and alcohol 
consumption in this analysis [40], and an earlier systematic review of estimates from 
published studies reported non-significant increased risk associations for regular mouthwash 
use [41]  
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Human papillomavirus (HPV) 
Oral human papillomavirus (HPV) is mainly associated with oropharyngeal (rather than oral 
cavity) cancer risk. There are over 200 HPV types, but as with cervical cancer, HPV 16 and 
18 subtypes are the main high-risk oncogenic types [42]. Substantial increased risk for 
oropharyngeal cancer (as high as 15 times greater) in those with HPV 16 have been 
identified – as in the groundbreaking 2007 New England Journal of Medicine study [43].  
However, the natural history (prevalence, persistence, and determinants) of oral HPV 
infection is not well understood, nor is how carriage of oral HPV leads to oropharyngeal 
cancer. A large US population survey of oral prevalence of HPV infection found an overall 
7% prevalence, with bimodal peaks at 10% in 25-30 and 50-55-year-olds in men [44]. Risk 
factors for oral HPV carriage were also identified. These included smoking, alcohol, number 
of sexual partners, number of oral sex partners, and open mouth kissing. A small feasibility 
study in Scotland replicated these broad prevalence findings [45].  
Oral HPV is sexually transmitted [42]. INHANCE studies also point to a slight increased risk 
for oropharyngeal cancer with 6 or more lifetime sexual partners, 4 or more lifetime oral sex 
partners, and early age (<18 years) of sexual debut [46]. 
World-wide, the estimated HPV-attributable fraction of oropharyngeal cancer was 18-28%, 
but with estimates approaching 70% in the US [47]. A meta-analysis, including 5,396 
oropharyngeal cancer cases, observed increases from 40.5% before 2000 to 72.2% after 
2005, with significant increases observed in North America and Europe [48]. A recent 
international multi-centre case-control study, which included UK data and harmonised 
analyses, found HPV positive oropharyngeal cancer case proportions of 60% of US, and 
31% in Europe (data collected on cases diagnosed in 2002-2004) [49]. Similarly, older 
European estimates of around 30% population attributable fraction for oropharyngeal cancer 
have been reported previously [50]. Thus, given that the epidemiology trends of rapid 
increases in oropharyngeal cancer, it seems reasonable to assume that the attributable 
proportion (in UK and Europe) is rising from around one-third of cases and perhaps 
approaching the US proportion of around two-thirds. It should be noted (even from US data) 
that the aetiological fraction for other cancers of the head and neck is considerably lower – 
perhaps as low as 3% for oral cavity cancer [51].  
 
Conclusions 
When discussing “oral cancer”, it is important to be clear and use the distinct terms: oral 
cavity cancer and oropharyngeal cancer. There is a need for agreed and standardised (ICD-
based) definitions of oral cavity cancer and oropharyngeal cancer to be adopted in 
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descriptive epidemiological reporting of disease burden and trends in Cancer Registries, and 
in analytical epidemiological analysis of risk. This is important given the increasing evidence 
of the differing and changing trends and risk factors across these cancers.  
The recent and projected increases of oral cavity and especially oropharyngeal cancer in the 
UK underlines the need for prioritising the development of cancer control strategies and 
cancer treatment services for those diagnosed.  
The risk data reviewed has demonstrated the well known role of tobacco and alcohol in the 
aetiology of oral and oropharyngeal cancer. The strengthening evidence around HPV (in the 
case of oropharyngeal cancer), evidence on the benefits of quitting tobacco and alcohol use 
and further understanding of the role of diet, oral health, and genetics combined with the 
dominant role of socioeconomic factors and inequalities are all important in designing and 
managing both population and individual risk reduction strategies.  
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Table 1 Oral cancer definitions used in routine Cancer Registry publications in 
  the 4 countries of the UK   
 
Oral Cancer Subsite (ICD code)  
 
England 
 
N.Ireland 
 
Scotland 
 
Wales 
 
Proposed 
Standardised 
Definition 
External lip (C00.0 - C00.2) 
 
L OC P L OC P X OC OP X 
Lip (C00.3 - C00.9)  
 
L OC P L OC P OC OC OP OC 
Base of tongue, NOS (C01.0 - C1.09) 
L OC P L OC P OP OC OC OP OP 
Dorsal surface of tongue, NOS (C02.0 
- C02.3) 
L OC P L OC P OC OC OP OC 
Lingual tonsil (C02.4) 
 
L OC P L OC P OC OC OP OP 
Overlapping lesion of tongue, or 
tongue NOS (C02.8 - C02.9) 
L OC P L OC P OC OC OP OC 
Gum (C03) 
 
L OC P L OC P OC OC OP OC 
Floor of mouth (C04) 
 
L OC P L OC P OC OC OP OC 
Soft palate (C05.1)  
 
L OC P L OC P OC OC OC OP OC 
Uvula (C05.2) 
 
L OC P L OC P OC OC OC OP OC 
Overlapping lesion of palate or palate 
NOS (C05.8) 
L OC P L OC P OC OC OC OP OC 
Cheek mucosa (C06.0) 
 
L OC P L OC P OC OC OP OC 
Overlapping lesion of other and 
unspecified mouth (C06.8- C06.9) 
L OC P L OC P OC OC OP OC 
Mouth, NOS (C06.9) 
 
L OC P L OC P OC OC OP OC 
Salivary glands and parotid gland (C07 
- C08) 
L OC P L OC P X X X 
Tonsil (C09) 
 
L OC P L OC P OC OC OP OP 
Anterior surface of epiglottis (C10.1) 
 
L OC P L OC P OC OC OP OP 
Lateral wall of oropharynx (C10.2) 
 
L OC P L OC P OC OC OP OP 
Nasopharynx (C11) 
 
L OC P L OC P X X X 
Pyriform sinus (C12.9) 
 
L OC P L OC P X X X 
Hypopharynx (C13) 
 
L OC P L OC P X X X 
Pharynx NOS (C14.0) 
 
L OC P L OC P X X OP 
Waldeyer’s ring (C14.2) 
 
L OC P L OC P X X OP 
ICD : International Classification of Diseases; 
NOS : Not Otherwise Specified 
L OC P : Lip Oral Cavity Pharynx cancer 
OC : Oral Cavity cancer 
OP : Oropharyngeal cancer  
OC OP : Oral Cavity and Oropharyngeal cancer (combined)  
OPC: Oropharyngeal Cancer  
X : Excluded 
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 Table 2  Cancer Registry data from 4 UK countries showing oral cavity cancer 
and oropharyngeal cancer numbers (n) and (European) Age-
Standardised incidence rates per 100,000 person-years by gender  
Country / gender OCC 
Incidence rate (n) 
OPC 
Incidence rate (n) 
Year - most 
recently available 
data  
England Females 
                Males 
4.8 per 100,000 (1309) 
7.3 per 100,000 (1779) 
2.7 per 100,000 (712) 
9.1 per 100,000 (2265) 
2016 
N.Ireland Females 
                 Males     
3.9 per 100,000 (34) 
5.9 per 100,000 (46) 
 
2.1 per 100,000 (18) 
6.8 per 100,000 (55) 
2016 
Scotland Females 
                Males 
5.6 per 100,000 (160) 
10.0 per 100,000 (240) 
 
2.7 per 100,000 (77) 
9.7 per 100,000 (247) 
2016 
Wales  Females 
             Males 
3.7 per 100,000 (64) 
7.4 per 100,000 (112) 
 
2.9 per 100,000 (48) 
10.5 per 100,000 (159) 
2015 
OCC : Oral Cavity Cancer 
OPC : Oropharyngeal Cancer 
 
Figure 1 Trends in (European) Age-Standardised incidence rates (EASRs) of oral 
cavity cancer (OCC) and oropharyngeal cancer (OPC), males and 
females combined, for England, N.Ireland, and Scotland (2000-2016) and 
Wales (2000-2015), with total number of cases in period (n).  
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